NPCE NeuroPace Inc

Price (delayed)

$14.21

Market cap

$487.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.57

Enterprise value

$544.9M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 35

Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. ...

Highlights
NeuroPace's EPS has increased by 31% YoY and by 12% QoQ
NPCE's net income is up by 26% year-on-year and by 11% since the previous quarter
NPCE's equity is down by 39% year-on-year and by 18% since the previous quarter
NeuroPace's quick ratio has decreased by 13% YoY and by 11% QoQ

Key stats

What are the main financial stats of NPCE

NPCE stock price

How has the NeuroPace stock price performed over time
Intraday
-3.4%
1 week
0.78%
1 month
1.28%
1 year
36.77%
YTD
-7.97%
QTD
-10.57%

Financial performance

How have NeuroPace's revenue and profit performed over time
Revenue
$98.84M
Gross profit
$78.7M
Operating income
-$15.08M
Net income
-$19.11M
Gross margin
79.6%
Net margin
-19.3%
NeuroPace's operating margin has increased by 39% YoY and by 19% from the previous quarter
The net margin has increased by 37% YoY and by 15% from the previous quarter
The operating income has increased by 29% year-on-year and by 17% since the previous quarter
NPCE's net income is up by 26% year-on-year and by 11% since the previous quarter

Price vs fundamentals

How does NPCE's price correlate with its fundamentals

Growth

What is NeuroPace's growth rate over time

Valuation

What is NeuroPace stock price valuation
P/E
N/A
P/B
40.77
P/S
4.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.51
NeuroPace's EPS has increased by 31% YoY and by 12% QoQ
The price to book (P/B) is 162% higher than the 5-year quarterly average of 16.1 and 39% higher than the last 4 quarters average of 30.4
NPCE's equity is down by 39% year-on-year and by 18% since the previous quarter
NPCE's price to sales (P/S) is 30% more than its 5-year quarterly average of 3.9 and 8% more than its last 4 quarters average of 4.7
NPCE's revenue is up by 17% year-on-year and by 3.5% since the previous quarter

Efficiency

How efficient is NeuroPace business performance
NeuroPace's return on sales has increased by 37% YoY and by 16% QoQ
NeuroPace's ROE has increased by 29% YoY
The company's return on assets rose by 27% YoY and by 9% QoQ
NPCE's ROIC is up by 25% year-on-year and by 13% since the previous quarter

Dividends

What is NPCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NPCE.

Financial health

How did NeuroPace financials performed over time
NPCE's total assets is 14% higher than its total liabilities
NeuroPace's quick ratio has decreased by 13% YoY and by 11% QoQ
The company's current ratio fell by 10% YoY and by 8% QoQ
NeuroPace's debt to equity has surged by 60% YoY and by 21% QoQ
NPCE's equity is down by 39% year-on-year and by 18% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.